Hybrid Silica-Coated PLGA Nanoparticles for Enhanced Enzyme-Based Therapeutics
Preprint
- 1 December 2022
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Some cancer cells rely heavily on non-essential biomolecules for survival, growth, and proliferation. Enzyme based therapeutics can eliminate these biomolecules, thus specifically targeting neoplastic cells; however, enzyme therapeutics are susceptible to immune clearance, exhibit short half-lives, and require frequent administration. Encapsulation of therapeutic cargo within biocompatible and biodegradable poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) is a strategy for controlled release. Unfortunately, PLGA NPs exhibit burst release of cargo shortly after delivery or upon introduction to aqueous environments where they decompose via hydrolysis. Here we show the generation of hybrid silica-coated PLGA (SiLGA) NPs as viable drug delivery vehicles exhibiting sub-200 nm diameters, a metastable Zeta potential, and high loading efficiency and content. Compared to uncoated PLGA NPs, SiLGA NPs offer greater retention of enzymatic activity and slow the burst release of cargo. Thus, SiLGA encapsulation of therapeutic enzymes, such as asparaginase, could reduce frequency of administration, increase half-life, and improve efficacy for patients with a range of diseases.Keywords
All Related Versions
- Version 1, 2022-12-01, Preprints
- Published version: Pharmaceutics, 15 (1), 143.
This publication has 42 references indexed in Scilit:
- PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-upInternational Journal of Pharmaceutics, 2021
- Clinical effect and safety profile of pegzilarginase in patients with arginase 1 deficiencyJournal of Inherited Metabolic Disease, 2020
- Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticalsAdvanced Drug Delivery Reviews, 2020
- Pegaspargase: A Review in Acute Lymphoblastic LeukaemiaDrugs, 2019
- A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignanciesCancer Chemotherapy and Pharmacology, 2018
- A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 DiabetesAdvances in Therapy, 2017
- Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicinColloids and Surfaces B: Biointerfaces, 2016
- Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes MellitusDrugs, 2015
- Asparaginase Erwinia chrysanthemi (Erwinaze®): A Guide to Its Use in Acute Lymphoblastic Leukemia in the USABioDrugs, 2013
- Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosisFertility and Sterility, 2004